APC anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
145-2C11_APC_021606
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
  • 145-2C11_APC_021606
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) APC (filled histogram) or Armenian hamster IgG APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability
100311 25 µg $33.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100312 100 µg $105.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Wang Q, et al. 2020. Radiat Environ Biophys. 59:89. PubMed
  2. Nelson J, et al. 2020. Sci Adv. 6:eaaz6893. PubMed
  3. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  4. Wang B, et al. 2022. EMBO J. 41:e108946. PubMed
  5. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  6. Cha JH, et al. 2022. J Biol Chem. 298:101817. PubMed
  7. Khayrullina G, et al. 2022. Glia. 70:1337. PubMed
  8. Gargaro M, et al. 2022. Immunity. 55:1032. PubMed
  9. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  10. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  11. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  12. Agrafiotis A, et al. 2023. Acta Neuropathol. 145:335. PubMed
  13. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  14. Drijvers JM, et al. 2021. Cancer Immunol Res. 9:184. PubMed
  15. Sohn J, et al. 2022. Blood Adv. 6:2557. PubMed
  16. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  17. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  18. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  19. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  20. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  21. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  22. van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed
  23. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  24. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  25. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  26. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  27. Fujimori S, et al. 2022. Elife. 11:. PubMed
  28. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  29. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  30. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  31. Pennock N, et al. 2014. Proc Natl Acad Sci U S A. 111:16472. PubMed
  32. Ajina R, et al. 2019. Oncoimmunology. 8:e1577127. PubMed
  33. Okamoto M, et al. 2014. J Immunol. 192:2770. PubMed
  34. Nakamura M, et al. 2015. J Immunol. 194:243. PubMed
  35. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  36. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  37. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  38. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  39. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  40. Ku M, et al. 2016. Mol Cancer Ther. 15: 1975 - 1987. PubMed
  41. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  42. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  43. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  44. Jung BG, et al. 2022. PLoS Pathog. 18:e1010454. PubMed
  45. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  46. Zhou H, et al. 2022. EMBO Rep. 23:e53475. PubMed
  47. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  48. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  49. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  50. Gao JL, et al. 2019. JCI Insight. 4:e132140. PubMed
  51. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  52. Wang J, et al. 2018. Front Immunol. 9:371. PubMed
  53. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  54. Wan W, et al. 2015. Cardiovasc Res. 106:478. PubMed
  55. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  56. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  57. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  58. Leiva M, et al. 2016. Nat Commun. 7:10222. PubMed
  59. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  60. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  61. Dong S, et al. 2021. Nature. 591:117. PubMed
  62. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
  63. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  64. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  65. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  66. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  67. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  68. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  69. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  70. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  71. Siggs O, et al. 2015. Proc Natl Acad Sci U S A. 112: E5706 - E5714. PubMed
  72. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  73. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  74. Oksenych V, et al. 2021. Biomolecules. 12:. PubMed
  75. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  76. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  77. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  78. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  79. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  80. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  81. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  82. Uto T, et al. 2016. Nat Commun. 7: 11273. PubMed
  83. Rovira-Clavé X, et al. 2016. J Leukoc Biol. 99: 143 - 152. PubMed
  84. XS R, et al. 2015. Diabetes. 64 90. PubMed
  85. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  86. Ghandhi SA, et al. 2019. Sci Rep. 9:19434. PubMed
  87. Xia P et al. 2018. Immunity. 48(4):688-701 . PubMed
  88. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  89. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  90. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  91. Liu Y, et al. 2022. Am J Transl Res. 14:6856. PubMed
  92. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  93. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  94. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  95. Zhang Q, et al. 2022. JCI Insight. 7:. PubMed
  96. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  97. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  98. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  99. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  100. Liang Q, et al. 2020. Front Microbiol. 11:571847. PubMed
  101. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  102. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  103. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  104. Omatsu Y, et al. 2022. Nat Commun. 13:2654. PubMed
  105. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  106. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  107. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  108. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  109. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  110. Castañeda–Zegarra S, et al. 2019. Biomolecules. 0.929166667. PubMed
  111. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  112. Düking T, et al. 2022. Sci Adv. 8:eabo7639. PubMed
  113. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  114. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  115. Koide S, et al. 2022. iScience. 25:103603. PubMed
  116. Bergquist M, et al. 2014. J Infect. 69:113. PubMed
  117. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  118. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  119. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  120. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  121. Sato Y, et al. 2022. Front Mol Biosci. 9:1040237. PubMed
  122. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  123. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  124. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  125. Stephens HM, et al. 2022. Methods Mol Biol. 2478:727. PubMed
  126. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  127. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  128. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  129. Arensman MD, et al. 2020. Oncoimmunology. 9:1800162. PubMed
  130. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  131. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  132. Xu G, et al. 2015. Free Radic Biol Med. 87: 15-25. PubMed
  133. Cruz F, et al. 2016. Stem Cells Trans Med. 5: 488-499. PubMed
  134. Huang X, et al. 2021. Immunity. . PubMed
  135. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  136. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  137. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  138. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  139. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  140. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  141. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
  142. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  143. Tong Y, et al. 2018. EBioMedicine. 39:132. PubMed
RRID
AB_312676 (BioLegend Cat. No. 100311)
AB_312676 (BioLegend Cat. No. 100312)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account